Interestingly, inhibition of HER-2/neutyrosine kinase activity in a prostate cancer model prevents PPARγ degradation and thereby enhancessusceptibility to PPARγ activators such as R-etodolac [81]. The gene discussed is PPARG; the disease is prostate carcinoma.